Orikami develops AI-driven software that translates real patient data into clinically validated digital biomarkers to support treatment decisions. Its platform continuously monitors patients to identify data patterns that inform more personalized medication choices. The technology is positioned for complex chronic illnesses, including neurologic disorders such as Multiple Sclerosis and Parkinson’s. Orikami says its products are clinically validated and certified after five years of work on those processes. The company is actively seeking collaborations with pharmaceutical firms to expand use cases. Healthy.Capital is investing to enable a real‑world test and initial patient rollout, reflecting early commercial validation efforts.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2019